BACKGROUND: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens. METHODS: We compared rituximab with cyclophosphamide as induction therapy in ANCA-associated vascu...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record